Thalassemia testing market - 2024-2031

Thalassemia testing market - 2024-2031

Global Thalassemia Testing Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2031 growing at a CAGR of YY% during the forecast period 2024-2031.

Thalassemia is characterized by a genetic deficiency in the synthesis of alpha and beta-globin chains. The signs and symptoms of thalassemia appear within the first 2 years of life and many people with thalassemia major have severe symptoms that require frequent blood transfusions to replenish the red blood cell supply.

Thalassemia testing aims to detect the presence of thalassemia traits, determine the type of thalassemia, and provide information essential for proper management and treatment. Thalassemia testing is typically conducted in a step-wise procedure with initial screening tests such as CBC (complete blood count) and hemoglobin electrophoresis followed by more specific tests, including DNA analysis for confirmation and detailed characterization.

Market Dynamics

Increasing prevalence of thalassemia

The increasing prevalence of thalassemia acts as a significant driver for market growth. High prevalence often correlates with a higher incidence of thalassemia cases. Early diagnosis is essential for effective disease management and intervention. Thalassemia testing allows for the identification of affected individuals, enabling healthcare professionals to implement appropriate treatment plans and supportive care early in life.

For instance, a high prevalence of thalassemia has still been reported in southern China due to the lack of PND and genetic counseling. The overall prevalence of α-thalassemia, β-thalassemia, and α + β-thalassemia was 7.880%, 2.210%, and 0.480%, respectively.

Also, according to an article published in the National Library of Medicine 2022, estimated that the prevalence of β-thal trait in Central India ranged between 1.4 and 3.4%, while 0.94% β-TM was reported among the patients with anemia.

Furthermore, significant growth drivers such as the increasing demand for prenatal testing, and advancements in genetic testing are expected to drive the market in the forecast period.

Limited patient awareness

Limited patient awareness regarding thalassemia is a significant challenge that can impact the early detection, management, and overall well-being of individuals with thalassemia. Public health campaigns and educational resources about thalassemia are limited in rural areas which leads to a lack of understanding among the general population and healthcare providers. Thus, the above factors can hamper the market growth.

Segment Analysis

The global thalassemia testing market is segmented based on type, testing type, product type, end user and region.

The beta thalassemia segment accounted for approximately 56.4% of the market share

The beta thalassemia segment is expected to hold the largest market share over the period forecast. It is characterized by a reduced production of beta-globin chains in hemoglobin. Hemoglobin is the protein in red blood cells that carries oxygen to the body's tissues. Beta thalassemia is caused by mutations in the HBB gene, which provides instructions for making the beta-globin protein.

Beta thalassemia is inherited in an autosomal recessive manner which is an individual needs to inherit a mutated beta-globin gene from both parents to develop the disorder. Also, Hemoglobin electrophoresis is a laboratory technique that separates different types of hemoglobin based on their electrical charge. This test also helps identify abnormal hemoglobin patterns associated with beta-thalassemia.

Geographical Analysis

North America is expected to hold a significant position in the global thalassemia testing market share

The global thalassemia testing market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as rising prevalence of thalassemia, research and development facilities, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.

For instance, in March 2023, Hemex Health was awarded $3 million to bring Gazelle, its point-of-care, a rapid diagnostic testing device for sickle cell disease (SCD) and beta-thalassemia in the United States. The Gazelle Hb Variant test is a smaller, automated version of electrophoresis.

Additionally, in the United States, the prevalence of β-thalassemia has increased by approximately 7.5% over the last 50 years. Hence, due to the above factors, it is expected to drive the region’s growth

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global thalassemia testing market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, reagents, and kits launches, and consultations worldwide. With the outbreak of the pandemic, many diagnostics centers faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the thalassemia testing market is expected to be moderately affected over the forecast period.

Market Segmentation

By Type
• Alpha thalassemia
• Beta thalassemia

By Testing Type
• Prenatal testing
• Complete blood count (CBC)
• Genetic Testing
• Others

By Product Type
• Laboratory Equipment
• Kits
• Reagent

By End User
• Hospitals and Clinics
• Diagnostic Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Bio-Rad Laboratories Inc., MedGenome, ViennaLab Diagnostics GmbH, Thermo Fisher Scientific Inc., Asper Biogen, Tosoh Europe N.V., Mapmygenome, Mylab Discovery Solutions Pvt. Ltd., Revvity Inc., and Matrix Labs among others.

Key Developments
• In June 2022, BGI Genomics received CE-IVDD approval for its thalassemia detection kit.

Why Purchase the Report?
• To visualize the global thalassemia testing market segmentation based on type, testing type, product type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global thalassemia testing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global thalassemia testing market report would provide approximately 71 tables, 69 figures, and 185 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies